COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A PURINE ANALOG

Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

[Figure 5]